A new protein structure may guide the development of Alzheimer’s therapeutics.
An inhibitor of cell metabolism may be a good therapeutic target for neuroblastoma, which accounts for about 15 percent of pediatric cancer-related deaths.
Vanderbilt investigators have discovered that activated epidermal growth factor receptor may be a target for therapies to prevent colorectal cancer development.
A signaling protein overexpressed in upper gastrointestinal cancers is an attractive therapeutic target.
Some memory deficits observed in Alzheimer’s disease may be due to co-morbid illnesses – not the disease itself – and may be reversed by lifestyle changes or pharmacologic interventions.
An enzyme in macrophage immune cells may be a good target for treating chronic infections, Vanderbilt researchers have discovered.